AXNX:NSD-Axonics Modulation Technologies Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 68.48

Change

+0.04 (+0.06)%

Market Cap

USD 3.50B

Volume

0.44M

Analyst Target

USD 52.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 27.98B
PODD Insulet Corporation

N/A

USD 15.15B
BRKR Bruker Corporation

N/A

USD 9.75B
MASI Masimo Corporation

N/A

USD 6.15B
TMDX TransMedics Group Inc

N/A

USD 5.60B
PRCT Procept Biorobotics Corp

N/A

USD 4.10B
QDEL Quidel Corporation

N/A

USD 2.76B
TNDM Tandem Diabetes Care Inc

N/A

USD 2.69B
LIVN LivaNova PLC

N/A

USD 2.66B
NARI Inari Medical Inc

N/A

USD 2.53B

ETFs Containing AXNX

MARB First Trust Vivaldi Merge.. 4.07 % 0.00 %

N/A

USD 0.03B
EVNT AltShares Event-Driven ET.. 2.98 % 0.00 %

N/A

USD 4.81M
ARB AltShares Trust - AltShar.. 0.00 % 0.00 %

N/A

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.04% 74% C 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.04% 74% C 67% D+
Trailing 12 Months  
Capital Gain 14.32% 81% B- 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.32% 81% B- 69% C-
Trailing 5 Years  
Capital Gain 89.64% 92% A 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.64% 92% A 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 25.50% 77% C+ 82% B
Dividend Return 25.50% 77% C+ 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.34% 73% C 44% F
Risk Adjusted Return 63.21% 95% A 86% B+
Market Capitalization 3.50B 94% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.